银屑病与心血管共病关系的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.04.003

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (4): 453-456.DOI: 10.3760/cma.j.issn.1007-1245.2023.04.003

银屑病与心血管共病关系的研究进展

吴雪梅张玉杰解胜华

滨州医学院附属医院皮肤科，滨州　256600

收稿日期:2022-08-02 出版日期:2023-03-15 发布日期:2023-03-05
通讯作者: 张玉杰，Email：byfyzyj@126.com

Psoriasis and its cardiovascular system comorbidities

Wu Xuemei, Zhang Yujie, Xie Shenghua

Department of Dermatology, Binzhou Medical University Hospital, Binzhou 256600, China

Received:2022-08-02 Online:2023-03-15 Published:2023-03-05
Contact: Zhang Yujie, Email: byfyzyj@126.com

摘要/Abstract

摘要：

银屑病是一种免疫介导的慢性、复发性、炎症性疾病。不仅累及皮肤、指甲、关节，还可同时累及心血管、消化、内分泌等多个系统引起共病的发生。共同的致病炎症途径、相同的基因背景可能是共病发生的原因。本文就银屑病与心血管系统共病的研究进展进行综合评述。

关键词:

银屑病 , 共病, 心血管疾病, 研究进展

Abstract:

Psoriasis is a chronic, recurrent, inflammatory disease mediated by immunity that involves not only the skin, nails, and arthritis, but also multiple systems, such as cardiovascular, digestive, and endocrine systems. Common pathogenic inflammatory pathways and the same genetic background may be responsible for the occurrence of comorbidities. This paper reviews the research progress on psoriasis and its cardiovascular system comorbidities.

Key words:

Psoriasis, Comorbidities, Cardiovascular diseases, Research progress

吴雪梅张玉杰解胜华.

银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.

Wu Xuemei, Zhang Yujie, Xie Shenghua.

Psoriasis and its cardiovascular system comorbidities [J]. International Medicine and Health Guidance News, 2023, 29(4): 453-456.

参考文献

[1] 程龙龙,姜述堃,杜阳,等.银屑病的发病机制及其研究进展[J].医学综述,2019,25(2):227-232.DOI:10.3969/j.issn.1006-2084.2019.02.004.
[2] Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis[J]. J Eur Acad Dermatol Venereol, 2017,31(2):205-212. DOI: 10.1111/jdv.13854.
[3] 黄丹,陈崑.银屑病相关流行病学调查进展[J].诊断学理论与实践,2021,20(1):48-52.DOI:10.16150/j.1671-2870. 2021.01.007.
[4] Salahadeen E, Torp-Pedersen C, Gislason G, et al. Nationwide population-based study of cause-specific death rates in patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2015,29(5):1002-1005. DOI: 10.1111/jdv.12523.
[5] Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies[J]. J Am Heart Assoc, 2013,2(2):e000062. DOI: 10.1161/JAHA. 113.000062.
[6] Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events[J]. J Am Acad Dermatol, 2017,77(4):650-656.e3. DOI: 10.1016/j.jaad.2017.06.028.
[7] Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events[J]. Am J Med, 2011,124(8):775.e1-6. DOI: 10.1016/j.amjmed.2011.03.028.
[8] Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology[J]. J Am Acad Dermatol, 2017,76(3):377-390. DOI: 10.1016/j.jaad.2016.07.064.
[9] Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis[J]. J Invest Dermatol, 2006,126(10):2194-2201. DOI: 10.1038/sj.jid.5700410.
[10] Woo YR, Park CJ, Kang H, et al. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic[J]. Int J Mol Sci, 2020,21(19):7041. DOI: 10.3390/ijms21197041.
[11] 陈雪琴,宋志强.银屑病中主要免疫细胞和相关细胞因子的研究进展[J].中国皮肤性病学杂志,2020,34(11):1321-1325.DOI:10.13735/j.cjdv.1001-7089.201910054.
[12] Puig L. The role of IL 23 in the treatment of psoriasis[J]. Expert Rev Clin Immunol, 2017,13(6):525-534. DOI: 10.1080/1744666X.2017.1292137.
[13] Armstrong AW, Voyles SV, Armstrong EJ, et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis[J]. Exp Dermatol, 2011,20(7):544-549. DOI: 10.1111/j.1600-0625.2011.01308.x.
[14] Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis[J]. J Intern Med, 2008,263(5):517-527. DOI: 10.1111/j.1365-2796.2008. 01965.x.
[15] Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation[J]. Circulation, 2006,113(9):e382-385. DOI: 10.1161/CIRCULATIONAHA.105.595553.
[16] Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells[J]. Circulation, 2009,119(10):1424-32. DOI: 10.1161/CIRCULATIONAHA. 108.827618.
[17] Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease[J]. Med Hypotheses, 2004,63(4):696-698. DOI: 10.1016/j.mehy.2004.03.009.
[18] Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice[J]. J Immunol, 2009,183(12):8167-8175. DOI: 10.4049/jimmunol.0901126.
[19] Yan X, Shichita T, Katsumata Y, et al. Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction[J]. J Am Heart Assoc, 2012,1(5):e004408. DOI: 10.1161/JAHA.112.004408.
[20] Halevy S, Shalom G, Trattner A, et al. Melkersson-Rosenthal syndrome: a possible association with psoriasis[J]. J Am Acad Dermatol, 2012,67(4):795-796. doi: 10.1016/j.jaad.2012.04.022.
[21] Quillard T, Araújo HA, Franck G, et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion[J]. Eur Heart J, 2015,36(22):1394-1404. DOI: 10.1093/eurheartj/ehv044.
[22] Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis[J]. J Immunol, 2011,187(1):490-500. DOI: 10.4049/jimmunol.1100123.
[23] Grundtman C, Wick G. The autoimmune concept of atherosclerosis[J]. Curr Opin Lipidol, 2011,22(5):327-334. DOI: 10.1097/MOL.0b013e32834aa0c2.
[24] England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications[J]. BMJ, 2018,361:k1036. DOI: 10.1136/bmj.k1036.
[25] Wu MY, Li CJ, Hou MF, et al. New insights into the role of inflammation in the pathogenesis of atherosclerosis[J]. Int J Mol Sci, 2017,18(10):2034. DOI: 10.3390/ijms18102034.
[26] Wu JJ, Sundaram M, Cloutier M, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: an observational cohort study[J]. J Am Acad Dermatol, 2018,79(1):60-68. DOI: 10.1016/j.jaad.2018.02.050.
[27] Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study[J]. Circ Cardiovasc Imaging, 2020,13(9):e011199. DOI: 10.1161/CIRCIMAGING.120.011199.
[28] Jókai H, Szakonyi J, Kontár O, et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study[J]. J Am Acad Dermatol, 2013,69(4):523-529. DOI: 10.1016/j.jaad.2013.06.019.
[29] Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis[J]. J Invest Dermatol, 2013,133(10):2340-2346. DOI: 10.1038/jid.2013.149.
[30] Lu Y, Chen H, Nikamo P, et al. Association of cardiovascular and metabolic disease genes with psoriasis[J]. J Invest Dermatol, 2013,133(3):836-839. DOI: 10.1038/jid.2012.366.

银屑病与心血管共病关系的研究进展

Psoriasis and its cardiovascular system comorbidities

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics